Uptake of Rapid Diagnostic Aids for Sepsis Across Michigan Hospitals

Document Type

Conference Proceeding

Publication Date

5-2026

Publication Title

American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Multiple rapid diagnostic aids for sepsis identification have received regulatory approval in recent years, including BV (MeMed), Immunoscore (Prenosis), Intellisep (Cytovale), Monocyte Distribution Width (MDW, Beckman Coulter), Septicyte (ImmuneExpress), and TriVerity (Inflammatix). We sought to assess the uptake of these novel tests in Michigan hospitals. Methods: The Michigan Hospital Medicine Safety Consortium (HMS) is a multi-hospital collaborative quality initiative sponsored by Blue Cross Blue Shield of Michigan. Participating hospitals complete a twice-yearly survey about structures and processes of care to inform statewide quality improvement work. The designated HMS representative for each hospital completes the survey, compiling responses from relevant staff at their institution. The spring 2025 survey asked about the availability of rapid diagnostic aids for sepsis identification and how these tests are used if available. Results: All 68 participating hospitals (100%) completed the HMS spring 2025 survey. Five hospitals (7.4%) reported having the MDW test available. No other rapid diagnostic aid for sepsis identification was available at any HMS hospital. Among the 5 hospitals with MDW, 4 automatically measured MDW with every complete blood count with differential in the emergency department, whereas the remaining hospital did not specify when MDW was measured. Incorporation of MDW into clinical decision-making was left to clinician discretion. No hospitals reported sepsis screening or treatment protocols that incorporated novel rapid diagnostic aids for sepsis. Conclusions: There has been limited uptake of rapid diagnostic aids for sepsis identification into clinical practice to date. These findings highlight a gap between regulatory approval and clinical adoption, and suggests the need for studies to evaluate the clinical impact of rapid diagnostic aids for sepsis and barriers to their implementation.

Volume

212

Issue

S1

First Page

S4634

Last Page

S4634

Comments

American Thoracic Society International Conference, May 15-20, 2026, Orlando, FL

DOI

10.1093/ajrccm/aamag162.6209

Link to Full Text

Share

COinS